Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 9/20 | 0.33 |
| ▸ | DRD3 | P35462 | 8/20 | 0.33 |
| ▸ | DRD1 | P21728 | 5/20 | 0.33 |
| ▸ | DRD4 | P21917 | 5/20 | 0.33 |
| ▸ | DRD5 | P21918 | 5/20 | 0.33 |
| ▸ | HTR1D | P28221 | 3/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506497 | 0.85 | SLC2A1 (0.36) | SLC2A1ALOX15TSHRHSD17B10DRD2 | |
| SCHEMBL12533716 | 0.77 | STS (0.36) | SLC2A1DRD2DRD3DRD1DRD4 | |
| SCHEMBL5067536 | 0.76 | DRD2 (0.33) | SLC2A1DRD2DRD3DRD1DRD4 | |
| SCHEMBL1506403 | 0.75 | STS (0.34) | SLC2A1DRD2DRD3DRD1DRD4 | |
| SCHEMBL8201115 | 0.74 | KDM4E (0.47) | ALOX15TSHRHSD17B10DRD2DRD3 | |
| SCHEMBL10157971 | 0.74 | DRD2 (0.34) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL21468494 | 0.71 | PTPN1 (0.40) | STSEPAS1KDM4E | |
| SCHEMBL18821987 | 0.71 | KIF11 (0.42) | — | |
| SCHEMBL5026108 | 0.71 | STS (0.64) | ALOX15TSHRHSD17B10DRD2DRD3 | |
| SCHEMBL17048023 | 0.71 | DRD2 (0.36) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971595-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-16 | — | — | EP | disclosed |
| US-7910592-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910592-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| EP-1971595-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042892-A1 | Cetp Inhibitors | CETP, APOB, MTTP | SLC2A1 2986/4885ALOX15 1762/4885TSHR 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.